Contrave and semaglutide-based medications work through very different pathways. Contrave combines naltrexone and bupropion, while semaglutide is a GLP-1 receptor agonist. Wegovy and Ozempic both contain semaglutide, but they are not interchangeable from a regulatory standpoint: Wegovy is specifically approved for chronic weight management in eligible patients, while Ozempic is approved for type 2 diabetes and certain cardiovascular and kidney risk-reduction indications.
Contrave combines two oral medications that affect appetite and reward pathways in the central nervous system. It may be considered for eligible adults as part of a broader medical weight-management plan. Because bupropion can affect blood pressure, mood, seizure risk and medication interactions, candidacy requires a medical review.
Semaglutide acts on the GLP-1 receptor and can reduce appetite, increase satiety and slow gastric emptying. For patients seeking weight-management treatment, semaglutide treatment should be selected according to the specific product indication, medical history and treatment goals.
Wegovy contains semaglutide and is approved for chronic weight management in eligible patients. Contrave is an oral medication with a different mechanism. The choice is not simply a question of which medication is “stronger.” It depends on factors such as medical history, gastrointestinal tolerance, blood pressure, seizure history, psychiatric history, medication interactions, prior treatment response, cost and insurance coverage.
Ozempic also contains semaglutide, but its FDA-approved indications differ from Wegovy. Using the generic term “semaglutide” does not mean all branded products have the same indication or dose schedule. Patients should be evaluated for the product that best matches their medical needs.
Some patients may ask whether Contrave and Wegovy can be used at the same time. This is not a decision to make without medical supervision. The medications work through different pathways, and combining therapies can increase treatment complexity and side-effect burden. Whether combination therapy is appropriate depends on the patient’s medical history, current medications, blood pressure, seizure risk, gastrointestinal tolerance, treatment response, and other clinical factors. Patients should not add one medication to the other on their own.
Contrave may cause nausea, headache, constipation, dizziness, insomnia or increases in blood pressure in some patients. Semaglutide-based treatment commonly causes gastrointestinal effects such as nausea, vomiting, diarrhea or constipation, especially during dose escalation. Both require screening for contraindications, interactions and individual risk factors.
There is no single best medication for every patient. A physician-supervised program should evaluate the whole patient rather than choosing treatment by brand popularity alone. At our medical weight loss program in Los Angeles, medication selection is considered alongside nutrition, body composition, prior treatment response and ongoing monitoring.
Patients comparing treatment approaches may also review our GLP-1 weight loss, weight loss medications and nutrition and body composition pages.
Written and medically reviewed by David Nazarian, MD, Board Certified in Internal Medicine. This article is for general education and is not a substitute for individualized medical care.
